|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 穿支皮瓣的发展与临床应用进展显示文摘 | 张世民 徐达传 俞光荣 侯春林 | 2006 | 中国临床解剖学杂志2006，24，3： | 108 |
| 2 | Relationship between intestinal microbiota and ulcerative colitis:Mechanisms and clinical application of probiotics and fecal microbiota transplantation显示文摘Ulcerative colitis(UC) is an inflammatory disease that mainly affects the colon and rectum. It is believed that genetic factors, host immune system disorders, intestinal microbiota dysbiosis, and environmental factors contribute to the pathogenesis of UC. however, studies on the role of intestinal microbiota in the pathogenesis of UC have been inconclusive. Studies have shown that probiotics improve intestinal mucosa barrier function and immune system function and promote secretion of anti-inflammatory factors, thereby inhibiting the growth of harmful bacteria in the intestine. Fecal microbiota transplantation(FMT) can reduce bowel permeability and thus the severity of disease by increasing the production of short-chain fatty acids, especially butyrate, which help maintain the integrity of the epithelial barrier. FMT can also restore immune dysbiosis by inhibiting Th1 differentiation, activity of T cells, leukocyte adhesion, and production of inflammatory factors. Probiotics and FMT are being increasingly used to treat UC, but their use is controversial because of uncertain efficacy. Here, we briefly review the role of intestinal microbiota in thepathogenesis and treatment of UC. | Zhao-hua Shen Chang-xin Zhu Yong-sheng Quan Zhen-yu Yang Shuai Wu Wei-wei Luo Bei Tan Xiao-yan Wang | 2018 | World Journal of Gastroenterology2018，24，1： | 111 |
| 3 | Advanced gastric cancer:Current treatment landscape and future perspectives显示文摘Gastric cancer currently ranks fourth in cancer-related mortality worldwide. In the western world, it is most often diagnosed at an advanced stage, after becoming metastatic at distant sites. Patients with advanced disease(locally advanced or metastatic) have a somber prognosis, with a median overall survival of 10-12 mo, and palliative chemotherapy is the mainstay of treatment. In recent years, novel approaches using inhibition of human epidermal growth factor receptor 2(HER2) have demonstrated significant improvements in progression-free and overall survival, compared with chemotherapy alone, in first-line treatment of patients with overexpression of HER2. In addition, both second-line chemotherapy and treatment with the vascular endothelial growth factor receptor-inhibitor ramucirumab demonstrated significant benefits in terms of overall survival, compared with best supportive care, in randomized studies. Moreover, ramucirumab in combination with chemotherapy demonstrated further significant benefits in terms of progression-free and overall survival, compared with chemotherapy alone, in second-line treatment for patients with metastatic gastric cancer. A recently published molecular classification of gastric cancer is expected to improve patient stratification and selection for clinical trials and provide a roadmap for future drug development. Nevertheless, despite these developments the prognosis of patients with advanced gastric cancer remains poor. In this review we discuss current standards of care and outline major topics of drug development in gastric cancer. | Antonia Digklia Anna Dorothea Wagner | 2016 | World Journal of Gastroenterology2016，22，8： | 108 |
| 4 | 国际临床骨密度学会共识文件(2005年版)显示文摘国际临床骨密度学会(InternationalsocietyforclinicaldensitometryISCD)是由多个学科专业人员参与的骨密度测量临床应用的国际学术组织。ISCD的学术委员会定期对发表的论文和研究结果进行分析,并提出共识文件。ISCD于2003年11月发表了第1版共识文件的译文已经在本刊2004年第4期上发表。ISCD学术委员会于2005年9月根据近2年的发展对前1版共识文件进行了修改,并形成了新的共识文件(2005年版),新增加的内容用隶书体标出。 | 程晓光(译) 刘忠厚(校) | 2006 | 中国骨质疏松杂志2006，12，2： | 68 |
| 5 | Can Chinese Medicine Be Used for Prevention of Corona Virus Disease 2019 (COVID-19)? A Review of Historical Classics, Research Evidence and Current Prevention Programs显示文摘Objective:Since December 2019,an outbreak of corona virus disease 2019(COVID-19)occurred in Wuhan,and rapidly spread to almost all parts of China.This was followed by prevention programs recommending Chinese medicine(CM)for the prevention.In order to provide evidenee for CM recommendations,we reviewed ancient classics and human studies.Methods:Historical records on prevention and treatment of infections in CM classics,clinical evidence of CM on the prevention of severe acute respiratory syndrome(SARS)and H1N1 in flue nza,and CM preve ntion programs issued by health authorities in China since the COVID-19 outbreak were retrieved from differe nt databases and websites till 12 February,2020.Research evide nee in eluded data from clinical trials,cohort or other population studies using CM for preventing contagious respiratory virus diseases.Results:The use of CM to prevent epidemics of infectious diseases was traced back to ancient Chinese practice cited in Huangdi's Internal Classic(Huang Di Nei Jing)where preventive effects were recorded.There were 3 studies using CM for prevention of SARS and 4 studies for H1N1 influenza.None of the participants who took CM contracted SARS in the 3 studies.The infection rate of H1N1 in flue nza in the CM group was significantly lower than the non-CM group(relative risk 0.36,95%confidence interval 0.24-0.52;n=4).For prevention of COVID-19,23 provinces in China issued CM programs.The main principles of CM use were to tonify qi to protect from external pathoge ns,disperse wind and discharge heat,and resolve damp ness.The most frequently used herbs in eluded Radix astragali(Huangqi),Radix glycyrrhizae(Gancao),Radix saposhnikoviae(Fangfeng),Rhizoma Atractylodis Macrocephalae(Baizhu),Lonicerae Japonicae Flos(Jinyinhua),and Fructus forsythia(Lianqiao).Conclusions:Based on historical records and human evidenee of SARS and H1N1 influenza prevention,Chinese herbal formula could be an alternative approach for prevention of COVID-19 in high-risk population.Prospective,rigorous population studies are warranted to confirm the potential preventive effect of CM. | LUO Hui TANG Qiao-ling SHANG Ya-xi LIANG Shi-bing YANG Ming Nicola Robinson LIU Jian-ping | 2020 | Chinese Journal of Integrative Medicine2020，26，4： | 61 |
| 6 | Risk factors and clinical characteristics of portal vein thrombosis after splenectomy in patients with liver cirrhosis显示文摘BACKGROUND:Portal vein thrombosis(PVT) is a potential lethal complication and may have negative influence on the prognosis after splenectomy in patients with liver cirrhosis.Prevention and timely detection of PVT are quite significant.There is a lack of knowledge about the clinical features and risk factors of PVT.Our study aimed to investigate the risk factors and clinical characteristics of PVT in order to figure out the high-risk individuals.METHODS:We collected the clinical data of 472 consecutive patients with non-neoplastic liver cirrhosis who had undergone splenectomy from January 2008 to December 2010 in our institution.Clinical and surgical characteristics of patients who developed PVT postoperatively and those who did not develop PVT were compared.Univariate and multivariate analyses of risk factors of PVT were performed.The mortality and rebleeding rate of the patients were also evaluated.RESULTS:Of the 472 patients,52 were excluded from the study.PVT developed in 71(71/420,16.9%) patients.Multivariate analysis revealed that wider preoperative portal vein diameter,postoperative thrombocytosis,prolonged prothrombin time and periesophagogastric devascularization were significantly correlated with PVT development [odds ratio(OR):5.701,2.807,1.850 and 2.090,respectively].The incidence of PVT in patients who took antiplatelet drugs was not lower than that in those who did not.Follow-up showed that patients in the PVT group had a tendency towards reduced overall survival but it was not statistically significant.Gastrointestinal bleeding occurred more often in the PVT group than that in the non-PVT group(P=0.044).CONCLUSIONS:Wider preoperative portal vein diameter,postoperative thrombocytosis,prolonged prothrombin time and periesophagogastric devascularization are independent risk factors of PVT.PVT is related with higher risk of postoperative gastrointestinal hemorrhage but has no significant impact on the overall survival. | Mu-Xing Li Xu-Feng Zhang Zheng-Wen Liu Yi Lv | 2013 | Hepatobiliary & Pancreatic Diseases International2013，12，5： | 57 |
| 7 | Current guidelines for the management of non-alcoholic fatty liver disease:A systematic review with comparative analysis显示文摘The current epidemic of non-alcoholic fatty liver disease(NAFLD) is reshaping the field of hepatology all around the world.The widespread diffusion of metabolic risk factors such as obesity,type2-diabetes mellitus,and dyslipidemia has led to a worldwide diffusion of NAFLD.In parallel to the increased availability of effective anti-viral agents,NAFLD is rapidly becoming the most common cause of chronic liver disease in Western Countries,and a similar trend is expected in Eastern Countries in the next years.This epidemic and its consequences have prompted experts from all over the word in identifying effective strategies for the diagnosis,management,and treatment of NAFLD.Different scientific societies from Europe,America,and Asia-Pacific regions have proposed guidelines based on the most recent evidence about NAFLD.These guidelines are consistent with the key elements in the management of NAFLD,but still,show significant difference about some critical points.We reviewed the current literature in English language to identify the most recent scientific guidelines about NAFLD with the aim to find and critically analyse the main differences.We distinguished guidelines from 5 different scientific societies whose reputation is worldwide recognised and who are representative of the clinical practice in different geographical regions.Differences were noted in: the definition of NAFLD,the opportunity of NAFLD screening in high-risk patients,the noninvasive test proposed for the diagnosis of NAFLD and the identification of NAFLD patients with advanced fibrosis,in the follow-up protocols and,finally,in the treatment strategy(especially in the proposed pharmacological management).These difference have been discussed in the light of the possible evolution of the scenario ofNAFLD in the next years. | Simona Leoni Francesco Tovoli Lucia Napoli Ilaria Serio Silvia Ferri Luigi Bolondi | 2018 | World Journal of Gastroenterology2018，24，30： | 42 |
| 8 | 慢性阻塞性肺病稳定期吸入治疗的最新进展显示文摘 | C B Cooper D P Tashkin 王同德(译) 代华平(校) | 2005 | 英国医学杂志中文版2005，8，5： | 37 |
| 9 | Chinese Stroke Association guidelines for clinical management of cerebrovascular disorders:executive summary and 2019 update of clinical management of stroke rehabilitation显示文摘Stroke is the third leading cause of long-term disability.Effective stroke rehabilitation should be provided to patients with a moderate or severe stroke so as to achieve functional recovery.Also,stroke rehabilitation is moving towards more intense therapy models that incorporate technologies such as robotics and computer games.Evidence-based guidelines are useful for promoting the best possible clinical practices.This guideline summarises the modes of stroke rehabilitation in China-three-stage rehabilitation network,rehabilitation of stroke dysfunction,training for activities of daily living,stroke complications and rehabilitation care.The aim of this guideline was to provide a synopsis of best clinical practices in the stroke rehabilitation of adult patients in China. | Tong Zhang Jun Zhao Xueping Li Yulong Bai Baojun Wang Yun Qu Bingjie Li Shengjie Zhao Chinese Stroke Association Stroke Council Guideline Writing Committee | 2020 | Stroke & Vascular Neurology2020，5，3： | 38 |
| 10 | The First Imported Case of Monkeypox in the Mainland of China—Chongqing Municipality,China,September 16,2022显示文摘Monkeypox is a zoonotic viral disease caused by the monkeypox virus(MPXV),and historically,all outbreaks have been linked to Africa;however,monkeypox has been posing an alarming challenge to the world in 2022(1)as approximately 60,000 cases have been reported in more than 100 nations and regions worldwide(2).Currently,many cases of monkeypox were identified in many nonendemic countries outside of Central and West Africa,and human-to-human transmission has occurred frequently,especially among men who have sex with men(MSM)presenting new clinical symptoms similar to syphilis and other sexually transmitted infections(3). | Hua Zhao Wenling Wang Li Zhao Sheng Ye Jingdong Song Roujian Lu Hua Zong Changcheng Wu Wei Huang Baoying Huang Yao Deng Ruhan A Wujuan Xie Li Qi Wenbo Xu Hua Ling Wenjie Tan | 2022 | China CDC weekly2022，4，38： | 35 |
| 11 | Hepatitis B virus genotypes and genome characteristics in China显示文摘AIM:To analyze the hepatitis B virus(HBV) characters in China,as well as the correlation between several HBV mutation and hepatitis symptoms.METHODS:A total of 1148 HBV genome sequences from patients throughout China were collected via the National Center For Biotechnology Information database(information including:genotype,territory and clinical status).HBV genotypes were classified by a direct reference from the Genbank sequence annotation,phylogenetic tree and online software analysis(http://gffzz16a62c593b5540cehckpnunwonb0c669x.ffgz.tsg.suse.edu.cn/projects/genotyping/formpage.cgi).The phylogenetic tree was constructed based on the neighbor-joining method by MEGA5.0 software.HBV sequences were grouped based on phylogenetic tree and the distance between the groups was calculated by using the computer between group mean distance methods.Seven hundred and twelve HBV sequences with clear annotation of clinical symptoms were selected to analyses the correlation of mutation and clinical symptoms.Characteristics of sequences were analyzed by using DNAStar and BioEdit software packages.The codon usage bias and RNA secondary structures analysis were performed by RNAdraw software.Recombination analysis was performed by using Simplot software.RESULTS:In China,HBV genotype C was the predominant in Northeastern,genotype B was predominant in Central Southern areas,genotype B and C were both dominant in Southwestern areas,and the recombinant genotype C/D was predominant in Northwestern areas.C2 and B2 were identified as the two major sub-genotypes,FJ386674 might be a putative sub-genotype as B10.The basal core promoter double mutation and pre-C mutation showed various significant differences between hepatitis symptoms.In addition to ATG,many other HBV initiation codons also exist.HBV has codon usage bias;the termination codon of X,C and P open reading frames(ORF) were TAA,TAG,and TGA,respectively.The major stop codons of S-ORF were TAA(96.45%) and TGA(83.60%) in B2 and C2 subtype,respectively.CONCLUSION:This study recapitulated the epidemiology of HBV in China,and the information might be meaningful critical for the future prevention and therapy of HBV infections. | Hong-Mei Li Jian-Qiong Wang Rui Wang Qian Zhao Li Li Jin-Ping Zhang Tao Shen | 2015 | World Journal of Gastroenterology2015，21，21： | 33 |
| 12 | Nonalcoholic fatty liver disease: Evolving paradigms显示文摘In the last years new evidence has accumulated on nonalcoholic fatty liver disease(NAFLD)challenging the paradigms that had been holding the scene over the previous 30 years.NAFLD has such an epidemic prevalence as to make it impossible to screen general population looking for NAFLD cases.Conversely,focusing on those cohorts of individuals exposed to the highest risk of NAFLD could be a more rational approach.NAFLD,which can be diagnosed with either non-invasive strategies or through liver biopsy,is a pathogenically complex and clinically heterogeneous disease.The existence of metabolic as opposed to genetic-associated disease,notably including'lean NAFLD'has recently been recognized.Moreover,NAFLD is a systemic condition,featuring metabolic,cardiovascular and(hepatic/extrahepatic)cancer risk.Among the clinico-laboratory features of NAFLD we discuss hyperuricemia,insulin resistance,atherosclerosis,gallstones,psoriasis and selected endocrine derangements.NAFLD is a precursor of type 2 diabetes(T2D)and metabolic syndrome and progressive liver disease develops in T2D patients in whom the course of disease is worsened by NAFLD.Finally,lifestyle changes and drug treatment options to be implemented in the individual patient are also critically discussed.In conclusion,this review emphasizes the new concepts on clinical and pathogenic heterogeneity of NAFLD,a systemic disorder with a multifactorial pathogenesis and protean clinical manifestations.It is highly prevalent in certain cohorts of individuals who are thus potentially amenable to selective screening strategies,intensive follow-up schedules for early identification of liver-related and extrahepatic complications and in whom earlier and more aggressive treatment schedules should be carried out whenever possible. | Amedeo Lonardo Fabio Nascimbeni Mauro Maurantonio Alessandra Marrazzo Luca Rinaldi Luigi Elio Adinolfi | 2017 | World Journal of Gastroenterology2017，23，36： | 33 |
| 13 | siRNA therapeutics:a clinical reality显示文摘Since the revolutionary discovery of RNA interference(RNAi),a remarkable progress has been achieved in understanding and harnessing gene silencing mechanism;especially in small interfering RNA(siRNA)therapeutics.Despite its tremendous potential benefits,major challenges in most siRNA therapeutics remains unchanged-safe,efficient and target oriented delivery of siRNA.Twenty years after the discovery of RNAi,siRNA therapeutics finally charts its way into clinics.As we journey through the decades,we reminisce the history of siRNA discovery and its application in a myriad of disease treatments.Herein,we highlight the breakthroughs in si RNA therapeutics,with special feature on the first FDA approved RNAi therapeutics Onpattro(Patisiran)and the consideration of effective siRNA delivery system focusing on current siRNA nanocarrier in clinical trials.Lastly,we present some challenges and multiple barriers that are yet to be fully overcome in siRNA therapeutics. | Phei Er Saw Er-Wei Song | 2020 | Science China(Life Sciences)2020，63，4： | 26 |
| 14 | Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma显示文摘Sorafenib, the unique drug as first-line treatment for advanced hepatocellular carcinoma (HCC), has opened a window of hope after searching for effective agents to combat HCC for decades. However, the overall outcomes are far from satisfactory. One of the explanations is the genetic heterogeneity of HCC, which has led to identifying predictive biomarkers for primary resistance to sorafenib, and then applying the concept of personalized medicine, or seeking therapeutic strategies such as combining sorafenib with other anticancer agents. Some of the combinations have demonstrated a better effectiveness than sorafenib alone, with good tolerance. The acquired resistance to sorafenib has also drawn attention. As a multikinase inhibitor, sorafenib targets several cellular signaling pathways but simultaneously or sequentially the addiction switches and compensatory pathways are activated. Several mechanisms are involved in the acquired resistance to sorafenib, such as crosstalks involving PI3K/Akt and JAK-STAT pathways, hypoxia-inducible pathways, epithelial-mesenchymal transition, etc . Based on the investigated mechanisms,some other molecular targeted drugs have been applied as second-line treatment for treat HCC after the failure of sorafenib therapy and more are under evaluation in clinical trials. However, the exact mechanisms accounting for sorafenib resistance remains unclear. Further investigation on the crosstalk and relationship of associated pathways will better our understanding of the mechanisms and help to find effective strategies for overcoming sorafenib resistance in HCC. | Bo Zhai Xue-Ying Sun | 2013 | World Journal of Hepatology2013，5，7： | 24 |
| 15 | Effects of antiviral therapy on preventing liver tumorigenesis and hepatocellular carcinoma recurrence显示文摘Chronic hepatitis B virus(HBV)infection is the key driving force of liver disease progression,resulting in the development of hepatic dysfunction,cirrhosis and hepatocellular carcinoma(HCC).The primary aim of therapy is to suppress or eliminate HBV replication to reduce the activity of hepatitis,thus reducing the risk of,or slowing the progression of,liver disease.Nucleos(t)ide analogues(Nucs)may result in rapid suppression of HBV replication with normalization of serum transaminases and restore liver function,thus increasing survival in patients with hepatic decompensation.Long-term Nuc therapy may result in histological improvement or reversal of advanced fibrosis and reduction in disease progression,including the development of HCC.The long-term benefits of a finite course of interferon(IFN)-αtherapy also include a sustained and cumulative response,as well as hepatitis B surface antigen seroclearance and reduction in the development of cirrhosis and/or HCC.Pegylated IFN and newer Nucs may achieve better long-term outcomes because of improved efficacy and a low risk of drug resistance.However,treatment outcomes are still far from satisfactory.Understanding the effects of anti-HBV treatment against HCC incidence and recurrence after hepatectomy or liver transplantation is required for further improvement of outcome. | Zhong-Ming Tan Bei-Cheng Sun | 2013 | World Journal of Gastroenterology2013，19，47： | 22 |
| 16 | Value of α-fetoprotein in association with clinicopathological features of hepatocellular carcinoma显示文摘AIM:To explore the relationship between α-fetoprotein(AFP) and various clinicopathological variables and different staging system of hepatocellular carcinoma(HCC) thoroughly.METHODS:A retrospective cohort study of consecutive patients diagnosed with HCC between January 2008 and December 2009 in West China Hospital was enrolled in our study.The association of serum AFP values with the HCC clinicopathological features was analysed by univariate and multivariate analysis,such as status of hepatitis B virus(HBV) infection,tumor size,tumor number,vascular invasion and degree of tumor differentiation.Also,patients were divided into four groups at the time of enrollment according to different cutoff values for serum value of AFP(≤ 20 μg/L,21-400 μg/L,401-800 μg/L,and ≥ 801 μg/L),to compare the positive rate of patient among four groups stratified by various clinicopathological variables.And the correlation of different kinds of tumor staging systems,such as TNM,Barcelona Clinic Liver Cancer(BCLC) staging classification and China staging,were compared with the serum concentration of AFP.RESULTS:A total of 2304 HCC patients were enrolled in this study totally;the mean serum level of AFP was 555.3 ± 546.6 μg/L.AFP levels were within the normal range(< 20 μg/L) in 27.4%(n = 631) of all the cases.81.4%(n = 1875) patients were infected with HBV,and those patients had much higher serum AFP level compared with non-HBV infection ones(573.9 ± 547.7 μg/L vs 398.4 ± 522.3 μg/L,P < 0.001).The AFP level in tumors ≥ 10 cm(808.4 ± 529.2 μg/L) was significantly higher(P < 0.001) than those with tumor size 5-10 cm(499.5 ± 536.4 μg/L) and with tumor size ≤ 5 cm(444.9 ± 514.2 μg/L).AFP levels increased significantly in patients with vascular invasion(694.1 ± 546.9 μg/L vs 502.1 ± 543.1 μg/L,P < 0.001).Patients with low tumor cell differentiation(559.2 ± 545.7 μg/L) had the significantly(P = 0.007) highest AFP level compared with high differentiation(207.3 ± 420.8 μg/L) and intermediate differentiation(527.9 ± 538.4 μg/L).In the multiple variables analysis,low tumor cell differentiation [OR 6.362,95%CI:2.891-15.382,P = 0.006] and tumor size(≥ 10 cm)(OR 5.215,95%CI:1.426-13.151,P = 0.012) were independent predictors of elevated AFP concentrations(AFP > 400 μg/L).Serum AFP levels differed significantly(P < 0.001) in the D stage of BCLC(625.7 ± 529.8 μg/L) compared with stage A(506.2 ± 537.4 μg/L) and B(590.1 ± 551.1 μg/L).CONCLUSION:HCC differentiation,size and vascular invasion have strong relationships with AFP,poor differentiation and HCC size ≥ 10 cm are independent predictors of elevated AFP.BCLC shows better relationship with | Chang Liu Guang-Qin Xiao Lu-Nan Yan Bo Li Li Jiang Tian-Fu Wen Wen-Tao Wang Ming-Qing Xu Jia-Yin Yang | 2013 | World Journal of Gastroenterology2013，19，11： | 22 |
| 17 | 腰椎后路椎间融合术后椎间融合的X线片及三维CT评价显示文摘目的 探讨X线片和三维CT(3D-CT)在判定单节段后路腰椎椎间融合术后椎间融合情况的临床价值.方法 选取接受后路腰椎椎间融合术并随访1年以上的患者43例,男19例,女24例;年龄16~74岁,平均47.2岁.峡部裂性滑脱21例,退变性滑脱15例,腰椎间盘突出并不稳症3例,腰椎间盘突出症复发3例,极外侧椎间盘突出症1例.单纯骨粒植骨26例,骨粒加椎间融合器17例.单节段内固定24例,双节段内固定19例.均为单节段椎间融合,其中L3,4,6例,L4,5,17例,L5 S1 20例.应用改良Brantigan评分判定腰椎正侧位X线片及3D-CT扫描所示椎间融合程度;动力位X线片判断椎间稳定性.结果 随访12~85个月,平均18个月.末次随访时X线片及3D-CT所示椎间融合率分别为64%(28/43例)和40%(17/43例).3D-CT的Brantigan评分小于正侧位X线片(P<0.05).根据诊断、固定节段及融合方式不同分组,各组3D-CT评分均低于正侧位X线片(P<0.05).动力位X线片示椎间不稳定者仅3例(7%).结论 腰椎3D-CT能更准确地评价椎间融合情况.拆除内固定前进行3D-CT检查非常必要.拆除内固定前摄动力位X线片对判定椎体间融合的临床意义不大. | 郑燕平 刘新宇 贾龙 王延国 黎君彦 | 2009 | 中华骨科杂志2009，29，12： | 22 |
| 18 | Critical Thinking Ⅰ: Seeking Conceptual Clarity显示文摘this first paper focuses on seeking conceptual clarity;the second paper will focus on how nurses use critical thinking in clinical cases;and the third paper will focus on how advanced nurse practitioners use critical thinking to provide safe and high quality care to patients and families.We welcome nursing colleagues in China respond our paper. | ZHAN Lin LEE Shirleatha FLEMING Belinda | 2014 | 护理学报2014，21，1： | 23 |
| 19 | 俯卧位通气对急性呼吸窘迫综合征患者预后影响的荟萃分析显示文摘目的:系统评价俯卧位通气(PPV)对急性呼吸窘迫综合征(ARDS)患者预后的影响。方法检索美国国家医学图书馆PubMed数据库、WebofScience、Cochrane系统评价和临床试验数据库、生物医学与药理学文摘数据库(EMBASE)、中国生物医学文献数据库(CBM)和中国期刊网全文数据库(CNKI)等数据库,系统收集相关随机对照临床试验(RCT)文献。按Cochrane系统评价方法筛选试验、评价质量、提取资料,采用RevMan5.1软件进行Meta分析。结果最终纳入10项临床对照试验,共2187例患者,全部为随机对照试验,研究质量为B或C。荟萃分析结果显示,与对照组比较,PPV可明显提高ARDS患者氧合指数(6h氧合指数比较:MD=28.19,95%CI为12.39~43.98,P=0.0005;4d氧合指数比较:MD=22.34,95%CI为10.77~33.91,P=0.0002;10d氧合指数比较:MD=18.07,95%CI为3.50~32.64,P=0.02)。与对照组比较,PPV能够降低总体死亡率(OR=0.75,95%CI为0.59~0.96,P=0.02),但ICU死亡率(OR=0.74,95%CI为0.51~1.05,P=0.09)、28d死亡率(OR=0.75,95%CI为0.44~1.29,P=0.30)、90d死亡率(OR=0.69,95%CI为0.30~1.60,P=0.39)及6个月死亡率(OR=0.88,95%CI为0.62~1.26,P=0.49)两组比较差异均无统计学意义。PPV组住ICU天数与对照组比较差异有统计学意义(MD=1.43,95%CI为0.38~2.48,P=0.007),而机械通气天数(受访90d)两组比较差异无统计学意义(MD=-0.42,95%CI为-1.56~0.72,P=0.47)。PPV组呼吸机相关肺炎发生率与对照组比较差异无统计学意义(OR=0.83,95%CI为0.62~1.13,P=0.24),压疮发生率PPV组高于对照组(OR=1.36,95%CI为1.06~1.74,P=0.01),意外拔管发生率两组比较差异无统计学意义(OR=0.94,95%CI为0.62~1.42,P=0.75),气胸发生率两组比较差异无统计学意义(OR=0.75,95%CI为0.45~1.25,P=0.27)。结论应用PPV治疗ARDS患者能明显提高氧合指数,降低总死亡率,尤其对于重度ARDS患者,可明显改善预后。 | 范平 石俊 陆杉 姚智渊 袁亮 朱曦 | 2014 | 中国急救医学2014，34，4： | 23 |
| 20 | Guidance for the clinical evaluation of traditional Chinese medicine-induced liver injury Issued by China Food and Drug Administration显示文摘1. Introduction Drug-induced liver injury (DILI), defined as liver injury caused by a drug and/or its metabolites, is a common clinical adverse drug reaction1–4. This type of injury can cause acute liver failure and even death in severe cases5. | Xiaohe Xiao Jianyuan Tang Yimin Mao Xiuhui Li Jiabo Wang Chenghai Liu Kewei Sun Yong’an Ye Zhengsheng Zou Cheng Peng Ling Yang Yuming Guo Zhaofang Bai Tingting He Jing Jing Fengyi Li Na An | 2019 | Acta Pharmaceutica Sinica B2019，9，3： | 22 |
您所在的机构暂未开通此部分的功能，请联系管理员